explore -WSS

explore

author：entertainment 2025-09-27 21:54:31 - browse：86775

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.

In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, in an earlier Phase 3 trial of the injectable drug Wegovy, people taking Wegovy lost about 6% of their body weight over the same time period.

Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Listen: Biogen's potential pivot, & Illumina's next chapter

focus

WSS

Stem cell treatment guidelines are released by FDA

'Ancient DNA,' 23andMe reveal African American ancestries

Advances in CAR

A rare thyroid diagnosis led to unexpected, all

What the cancer research community can learn from the Covid response

Gilgo Beach: Police identify another victim in serial killing investigation

hotspot

explore

leisure time

Moonlake's readout produced a cash windfall. Risks remain

Microsoft strikes partnership with Duke Health to advance health AI

Tori Bowie and the unacceptable rates of Black maternal death

Influencer to be charged after chaos erupts in New York City's Union Square

Apple is now the first public company to be valued at $3 trillion

How to fix cancer clinical trials' diversity problem

Moonlake's readout produced a cash windfall. Risks remain

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

Hepatitis C has a cure — but many Americans still lack access to it

Stem cell treatment guidelines are released by FDA

knowledge

My superpower is killing ticks

My superpower is killing ticks

Microsoft strikes partnership with Duke Health to advance health AI

ER docs worry over extreme heat as a 'mass casualty event'

Attacks on the drug industry will lead to fewer breakthroughs

The (many) problems with a new study criticizing cancer screening

focus

knowledge

focus

leisure time